MyFinsight
Home
Blog
About
Marketable securities
$983,339K
(121.01%↑ Y/Y)
Cash and cash
equivalents
$162,007K
(98.39%↑ Y/Y)
Prepaid expenses and
other current assets
$27,657K
(125.73%↑ Y/Y)
Total current assets
$1,173,003K
(117.69%↑ Y/Y)
Total assets
$1,173,003K
(117.69%↑ Y/Y)
Total liabilities,
convertible preferred stock...
$1,173,003K
(117.69%↑ Y/Y)
Total stockholders
equity
$1,101,141K
(141.60%↑ Y/Y)
Total liabilities
$71,862K
(-13.48%↓ Y/Y)
Accumulated deficit
-$1,232,840K
(-16.98%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$2,396K
(-627.75%↓ Y/Y)
Additional paid-in capital
$2,189,936K
(61.81%↑ Y/Y)
Total current
liabilities
$63,302K
(-23.79%↓ Y/Y)
Non-current cvr liability
$7,270K
Other non-current
liabilities
$1,290K
Preferred stock-Series
ANon Voting...
$146,425K
(0.00%↑ Y/Y)
Common stock, 0.0001
par value...
$16K
(23.08%↑ Y/Y)
Cvr liability
$31,350K
(-47.66%↓ Y/Y)
Accrued and other
current liabilities
$26,184K
(34.86%↑ Y/Y)
Accounts
payable-Nonrelated Party
$5,722K
(54.15%↑ Y/Y)
Related party accounts
payable-Related Party
$46K
(48.39%↑ Y/Y)
Back
Back
Balance Sheet
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)
source: myfinsight.com